Category: News

Blacksburg, VA – June 21, 2024 – TECHLAB, Inc., a part of the SSI Diagnostica Group, is pleased to announce that its C. DIFF QUIK CHEK COMPLETE^® test has received certification under the European In Vitro Diagnostic Medical Device Regulation (IVDR), a first* for a combined GDH plus toxin A/B test.

The C. DIFF QUIK CHEK COMPLETE^® test is a rapid membrane enzyme immunoassay designed for the simultaneous detection of Clostridioides difficile glutamate dehydrogenase (GDH) antigen and toxins A and B in a single reaction well. This innovative test provides both GDH and toxin results within approximately 30 minutes, enabling healthcare professionals to differentiate between active C. difficile infection and colonization in a cost-effective and clinically relevant manner.

“We are proud to achieve IVDR certification for our C. DIFF QUIK CHEK COMPLETE^® test,” said Christina Lindved, CEO of SSI Diagnostica Group, “This achievement underscores SSI Diagnostica’s commitment to delivering high-quality diagnostic tools that meet the stringent regulatory requirements and fulfill the needs of healthcare providers and patients worldwide.”

This certification recognizes the test’s adherence to rigorous quality and safety standards, ensuring its reliability and effectiveness in clinical settings across Europe, and marks a significant advancement in SSI Diagnostica’s efforts to enhance diagnostic capabilities for C. difficile infections.

For more information about the C. DIFF QUIK CHEK COMPLETE^® test and the TECHLAB portfolio of diagnostic solutions, please visit www.techlab.com.  To see the rest of the SSI Diagnostica Group portfolio, please visit www.ssidiagnostica.com.

* This assertion is based on a review of the EUDAMED database, 06/03/2024 at 10:00 am ET USA, which lists IVDR-compliant devices under code W0105011803.

About SSI Diagnostica Group

The SSI Diagnostica Group is a clinical diagnostic company with a mission to help prevent, monitor, and diagnose clinical diseases through quality portfolios of reagents and IVD diagnostic products and solutions. The Group specializes in gastric, respiratory and bloodborne diseases as a leading partner to the IVD and diagnostic industry. The company serves customers globally through its sites in Denmark, the USA, and China.  With a long heritage as a leading developer and manufacturer of intestinal diagnostics, TECHLAB, Inc. joined the SSI Diagnostica Group in 2022.

For media inquiries or further information, please contact:

Jodie Lee, M.S., M.B.A.

Director of Marketing

TECHLAB, Inc., a SSI Diagnostica Group company

Email: marketing@techlab.com

Phone: +1 (540) 953-1664

SSI Diagnostica Group is promoting Mie Nete Petersen to Vice President of Global Strategy & Corporate Development. She has undertaken a crucial role in developing our strategy and long-term growth ambition. Mie has extensive experience from large companies like Novo Nordisk and Coloplast working with strategy, commercial development and marketing before joining SSI Diagnostica in February 2022.

“To accelerate and deliver on our ambitious growth agenda, I’m happy to announce the promotion of Mie Petersen to Vice President. She has been a member of the Global Leadership Team since January 2023 and since then she has been leading the Global Strategy and Corporate Development function. She is a valuable resource to the Leadership, Board and organization. We are lucky to have such talents at SSI Diagnostica Group, and Mie will continue to be an immensely important resource to our growth and success,” says Christina Lindved, Group CEO.

SSI Diagnostica Group’s main goal is to serve the clinical diagnostic market in the effort of preventing, monitoring, and diagnosing people, ultimately supporting better treatment outcomes for patients globally.

In the effort to continuously strengthen the position with customers and be able to serve the IVD Diagnostics industry with quality diagnostics solutions, SSI Diagnostica Group is unifying its commercial sales and marketing regions for the diagnostics portfolio – kits and consumables. Cara Felish will join SSI Diagnostica Group as new head of this commercial division and step into the Global Leadership Team. Cara has extensive experience from the diagnostic, biotech, and pharmaceutical industry in various leadership positions from commercial operation and excellence, sales, and marketing.

“Our main goal is to serve the clinical diagnostic market in the effort of preventing, monitoring, and diagnosing people – supporting better treatment outcomes for patients globally. To accelerate and deliver on our exciting and ambitious growth agenda, we are happy Cara is joining SSI Diagnostica Group to strengthen the global commercial voice of our sales and marketing regions both internally and externally. Our business priorities should be founded on customer needs – and for this we need an aligned global commercial agenda and clear priorities for the global business to accelerate our effort in serving the market with our diagnostic solutions. With Cara’s proven leadership and focus on commercial excellence from both IVD and pharma industry, I am sure this will be a tremendous step in delivering on our priorities.” says Christina Lindved, Group CEO.

SSI Diagnostica Group is owned by Adelis Equity and embarked on a new 5-year strategy and growth plan in 2023 with the introduction of a new Executive and Leadership team. 

As part of our strategic focus on the Vaccine & IVD Industry, we’re delighted to announce new colleagues as part of our commercial team. We proudly welcome two dynamic individuals, each bringing a wealth of experience and passion from the clinical diagnostic industry to our organization:

Stuart McRoberts will be heading the Global Vaccine & IVD Industry Sales Division. Stuart comes with a proven track record as General Manager and Sales Leader in the IVD industry, and he joins us with extensive experience and a strong track record from Thermo Fisher Scientific, Sekisui, Phillips, Abbott, and more. We believe, Stuart’s leadership and industry experience makes him the ideal match to drive and execute our vaccine industry strategy.

Anna Engelund is appointed Head of Strategic Marketing, Reagents. Anna is a professional with a PhD in Neurobiology and an MSc in Biochemistry plus a rich background at Dako, Agilent, and Radiometer. Her expertise will be instrumental in aligning our commercial and portfolio strategy for continued success.

The extensive experience of Stuart and Anna will help us strengthen and accelerate how we commercially execute on serving the Vaccine & IVD Industry segment with our reagent portfolio to deliver on our strong ambition in this area.

SSI Diagnostica Group continues to strengthen the leadership team with the appointment of Finn Albrechtsen as the new Head of Global R&D. Finn has most recently held the CEO position at Vidya Ltd. (VC) as well as VP for R&D and Business Development at Thermo Fisher Scientific Microbiology Division. Prior to that Finn was Snr. Director at Agilent and the Diagnostics & Genomics Portfolio and Project Management Office (PMO). His combined experience within strategy execution, change management across product pipeline is a strong match to the SSID Group.

The fundamental DNA of our company is built on our specialization within Clinical Diagnostics & Surveillance of Infectious Disease for more than 100 years. As a trusted partner to the science community, Finn’s extensive experience within Microbiology and Clinical Diagnostics will help us prioritize and accelerate our R&D pipeline across the Group entities, says the Group CEO Christina Lindved.

The SSID Group has been owned By Adelis Equity Partners since 2016 and in May 2023 a new Chairman and Board of Directors was announced to strengthen the continuous growth journey.

Christina Lindved

CEO, SSI Diagnostica Group

We are delighted to announce the appointment of our new Chairman of the Board, Nachum (Homi) Shamir. Homi has significant top management and board experience, most recently as the longtime CEO and Chairman of the Board of Luminex Corporation, where he among other things led the successful acquisition of Nanosphere and the sale of the group to Diasorin. In addition to his significant general management experience, Homi brings deep experience within clinical diagnostics and medical devices. Homi has served on several boards over the years, including Given Imaging (acquired by Covidien), Cogentix Medical (acquired by Laborie Medical Technologies) and Invedo Medical (acquired by Ambu).

Ingo Chakravarty has also joined the Board of Directors of SSI Diagnostica Group. Ingo most recently served as President and CEO of Mesa Biotech which he successfully developed and grew until its sale to Thermo Fisher Scientific. Prior to this, Ingo has spent most of his career in infectious disease diagnostics at Roche, Hologic and GenMark. Separate to his Board role at SSI Diagnostica Group, Ingo is currently an operating partner at Northpond Ventures.

Following the acquisition of Techlab last year, SSI Diagnostica Group is now launching its new 5 year strategy. The aim is to further accelerate growth as one global organization serving the vaccine and IVD infectious disease markets. The strategy builds on the group’s strong position within gastric, respiratory and blood borne diseases, where the Group supports its customers in preventing disease outbreaks, disease surveillance and patient diagnostics.

Our new board members will contribute to the success of our strategy, and I very much look forward to the collaboration, says Christina Lindved, CEO of SSI Diagnostica Group.

In addition to Homi and Ingo, Stig Lokke Pedersen and Patrik Dahlen will continue to serve on the Board of Directors of the Group.

Rasmus Molander
Board member, SSI Diagnostica Group
Co-Managing Partner, Adelis Equity Partners